US3975511A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Solid phase radioimmunoassay
Assignee: Corning Glass Works
•
Filing: 1974-03-01
•
Granted: 1976-08-17
•
Expires: 1994-03-01
Abstract
Abstract Method of determining the concentration of a substance in a solution which comprises the steps of incubating the solution with a known amount of radioactively labelled substance and a suspendable composite consisting of anti-substance antibody coupled chemically through an intermediate silane coupling agent to an inorganic carrier, the incubation period being for a time sufficient to form immunochemical complexes, separating the complexes from the solution, determining the radioactivity of either the separated complexes or the remaining solution, and relating that determination to a standard curve. Specific assays for digoxin, insulin, and estriol are disclosed.
Inventors
- 👤 William P. Vann
- 👤 Sidney Yaverbaum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:53
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/551; G01N33/552; A; A61; A61K; A61K39/00; A61K39/395; A61K39/44; G01N33/74; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/815
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
112 words
A method for determining the concentration of digoxin in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled digoxin and a suspendable composite consisting of anti-digoxin antiserum coupled chemically through an intermediate silane coupling agent to a high surface area essentially water-insoluble inorganic carrier having an average particle size between about 0.05 and 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. centrifuging the complexes from the solution; c. counting the radioactivity of either the centrifuged complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of digoxin.
Claim 2
Independent Claim
112 words
A method for determining the concentration of digoxin in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled digoxin and a suspendable composite consisting of anti-digoxin antiserum coupled chemically through an intermediate silane coupling agent to a high surface area essentially water-insoluble inorganic carrier having an average particle size between about 0.05 and 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. centrifuging the complexes from the solution; c. counting the radioactivity of either the centrifuged complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of digoxin.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the incubation of step (a) is for at least 10 minutes.
Claim 4
Dependent Claim
25 words
The method of claim 2 wherein the inorganic carrier is porous and selected from the group consisting of porous glass particles and porous silica particles.
Claim 5
Dependent Claim
21 words
The method of claim 3 wherein the average pore diameter of the porous particles is between about 350A and about 1200A.
Claim 6
Independent Claim
113 words
A method for determining the concentration of insulin in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled insulin and a suspendable composite consisting of anti-insulin antibodies coupled chemically through a silane coupling agent to a high surface area, essentially water insoluble inorganic carrier having an average particle size between about 0.05 and about 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. separating the complexes from the solution; c. counting the radioactivity of either the separated complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of insulin.
Claim 7
Independent Claim
113 words
A method for determining the concentration of insulin in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled insulin and a suspendable composite consisting of anti-insulin antibodies coupled chemically through a silane coupling agent to a high surface area, essentially water insoluble inorganic carrier having an average particle size between about 0.05 and about 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. separating the complexes from the solution; c. counting the radioactivity of either the separated complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of insulin.
Claim 8
Dependent Claim
25 words
The method of claim 5 wherein the inorganic carrier is porous and selected from the group consisting of porous glass particles and porous silica particles.
Claim 9
Independent Claim
113 words
A method for determining the concentration of estriol in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled estriol and a suspendable composite consisting of anti-estriol antibodies coupled chemically through an intermediate silane coupling agent to a high surface area, essentially water-insoluble inorganic carrier having an average particle size between about 0.05 and about 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. separating the complexes from the solution; c. counting the radioactivity of either the separated complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of estriol.
Claim 10
Independent Claim
113 words
A method for determining the concentration of estriol in a solution which comprises the steps of: a. incubating the solution with a known amount of radioactively labelled estriol and a suspendable composite consisting of anti-estriol antibodies coupled chemically through an intermediate silane coupling agent to a high surface area, essentially water-insoluble inorganic carrier having an average particle size between about 0.05 and about 12 microns, the incubation being for a period sufficient to form immunochemical complexes; b. separating the complexes from the solution; c. counting the radioactivity of either the separated complexes or the remaining solution; and d. relating the count of step (c) to a standard to determine the concentration of estriol.
Claim 11
Dependent Claim
10 words
The method of claim 7 wherein the particles are porous.
Claim 12
Dependent Claim
12 words
The method of claim 8 wherein the particles consist of porous glass.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-08-17 | 1980-02-16 | 1980-08-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-08-17 | 1984-02-16 | 1984-08-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-08-17 | 1988-02-16 | 1988-08-17 | $7700.00 | Window Closed / Lapsed |